OncoMatch/Clinical Trials/NCT07202611
DC/NK Cell Therapy
Is NCT07202611 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies In vitro culture of autologous dendritic and natural killer cells for the treatment of patients with non-small cell lung cancer for lung cancer (nsclc).
Treatment: In vitro culture of autologous dendritic and natural killer cells for the treatment of patients with non-small cell lung cancer — Primary Outcomes The primary objective of this trial is to test the safety of formulations containing dendritic cells (DCs) and natural killer (NK) cells cultured in vitro. By evaluating the reactions following the administration of autologous dendritic cells via axillary lymph node injection and natural killer cells via intravenous injection, the study aims to determine the safety profile of these trial products for human use. Secondary Outcomes To verify the success rate of the cultured cell formulations and assess the cytotoxic capacity of natural killer cells in targeting and killing tumor cells. The evaluation of these secondary objectives involves analyzing specific subcategories, which can be divided into two major components: 1. Validation of Cultured Cell Preparation Success: Assessing the proliferation rate, recovery rate, survival rate, and tumor-killing capacity of the cultured autologous dendritic cells and natural killer cells. 2. Validation of Antitumor Effectiveness: Evaluating the antitumor efficacy of the trial products administered via axillary lymph node injection of autologous dendritic cells and intravenous infusion of autologous natural killer cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIIB, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — advanced
Must have received: anti-pd-1 therapy — advanced
Lab requirements
Blood counts
WBC: ≥3000/mm³; Lymphocytes: ≥1000/mm³; Hemoglobin: ≥10 g/dL; Platelets: ≥100,000/mm³
Kidney function
Creatinine: ≤1.25× ULN
Liver function
Total bilirubin: ≤1.5× ULN; SGOT (AST): ≤3× ULN; SGPT (ALT): ≤3× ULN
Normal Blood Count ... Normal Liver and Kidney Function (based on test results within 4 weeks before blood collection for cell preparation)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify